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OBJECTIVE 
To study the occurrence and types of neoplasms 
developed by patients who underwent an orthotopic 
cardiac transplantation under the Program of Cardiac 
Transplantation of Escola Paulista de Medicina, Federal 
University of São Paulo.  
METHODS 
This is an observational study of 106 patients who 
underwent orthotopic cardiac transplantation from 
November 1986 to September 2002 and survived at 
least thirty days following the procedure. The triple 
immunosuppressive regimen  given included cyclosporin 
A, azathioprine and a corticosteroid agent. Only two 
patients received OKT3 in addition to the regimen 
established. Mean follow-up was 61.4 months (ranging 
from two months to 192 months).
RESULTS
Twenty-three patients (21.3%) developed neoplasms 
– 56.5% of these were skin neoplasm, 30.1%, solid 
tumors, and 13.4% of post-transplant lymphoproliferative 
disease (PTLD). Mean interval between transplantation 
and diagnosis of neoplasm was: 54.9 months for skin 
neoplasm; 24.8 months for solid tumors and 70.3 months 
for PTLD.
CONCLUSION
Malignant neoplasms are relatively common in the 
population studied. Skin cancer was the most common type 
compared to the other types of neoplasms. Solid tumors 
were more frequently diagnosed than the lymphoproliferative 
diseases in the population examined.
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Heart surgery centers have progressively included 
orthotopic heart transplantation in their activities as a 
therapeutical option for managing patients with end-stage 
cardiac diseases. Advances in surgical and in myocardial 
preservation techniques, severe selection  of receptors, 
major progress in rejection control and ability to prevent 
and to treat several types of infections contributed to 
increase the survival of organ recipients1,2. In spite of this 
progress, the occurrence of late complications such as 
graft vascular disease and neoplasm affect the survival 
of these patients.
One of the first studies l inking neoplasms, 
transplantation and immunosuppression was published 
by Penn et al in 19693. Later several papers confi rmed 
the increase of the incidence of neoplasms in individuals 
who underwent transplantation4-9. If on the one hand the 
pharmacological advances in immunosuppressive therapy 
ensured a more effective control of acute rejection and 
increased the survival of patients in the short term, on 
the other the incidence of certain types of neoplasms 
is one of the main limiting factors in the long term for 
these patients2,10.
Patients who have undergone transplantation present a 
three to four-fold increased risk of developing a neoplasm 
compared to the general population; however this risk 
can be higher than a hundred-fold for certain types of 
neoplasms2,7. Mean length of time for post-transplant 
neoplasm to arise ranges from twelve to eighteen months. 
The estimate incidence of this type of disease is 1%-2% 
per year1. Skin and lip tumors are the most common 
in patients who undergo transplantation. However the 
incidence of many of the malignant neoplasms found in 
the general population (lungs, prostate, breast and colon) 
is not increased in the transplant population submitted 
to immunosuppression2.
Some tumors that are rarely observed in the general 
population are more common in patients who underwent 
transplantation, including non-Hodgkin lymphomas 
and lymphoproliferative disorders, currently gathered 
under the term Post-transplant lymphoproliferative 
Disorders (PTLD). The origin of PTLD is unclear but it 
is believed that it may depend on the monoclonal or 
polyclonal proliferation of B-lymphocytes infected with 
the Epstein-Barr virus. In addition to the neoplasms 
already mentioned, other types such as Kaposi’s 
sarcoma, renal carcinomas, in situ carcinoma of the 
cervix, hepatobiliary carcinomas, anogenital carcinomas 
and other sarcomas.
Skin and lip tumors in patients who undergo 
transplantation present some features that are rarely 
observed in the general population such as higher rate 
of squamous cell carcinomas compared to basal cell 
carcinomas11. Other unusual characteristics are the 
presence of tumors in several sites, frequent association 
with Kaposi’s sarcoma and increased incidence in 
younger patients12,13. Presence of anogenital neoplasms 
in patients younger than the general population is 
also observed2. In regard to PTLD, associations with 
the Epstein-Barr virus were observed: involvement of 
extranodal sites and marked preference for the brain and 
the transplanted organ12-17.
METHODS
An observational descriptive study of 129 patients 
who underwent orthotopic heart transplantation from 
November 1986 to September 2002 under the Heart 
Transplantation Program of Cardiovascular Surgery at 
the Escola Paulista de Medicina of the Federal University 
of São Paulo was conducted. Twenty-three patients out 
of the 129 died from different causes within a month 
following surgery and were therefore excluded from the 
study. The sample consisted of 106 patients: 87 men and 
19 women. At the time of transplantation the mean age 
was 43.7 years (ranging from 12 to 64 years).
Transplantation was indicated to treat the following 
heart conditions at their end-stage: idiopathic 
dilated cardiomyopathy: 44 patients (41.5%); 
Chagas’ cardiomyopathy: 31 patients (29.2%); 
ischemic cardiomyopathy: 23 patients (21.6%), 
peripartum cardiomyopathy: three patients (2.8%), 
other cardiomyopathies: fi ve (4.7%) (a hypertrophic, a 
congenital, a valvular, a viral and a post-radiotherapy 
cardiomyopathies). Signifi cant history of smoking was 
present in fi ve patients. All patients were submitted 
to immunosuppressive therapy with cyclosporine 
A, azathioprine and a cortiscosteroid agent. During 
that period, two patients also received orthoclone 
(OKT3) for treating rejection. Mean follow-up after the 
transplantation was 62.5 months (ranging from 2 to 
192 months).
Immunosuppressive therapy - The protocol of the 
immunosuppressive regimen consisted of cyclosporine A, 
azathioprine and corticosteroid as shown in Table 1.
Observations: The use of prednisone was discontinued 
at the second or third postoperative month in patients 
with Chagas’ disease or in those who developed diabetes 
or psychoses as complications because of the use of 
prednisone; Induction therapy was not applied; only two 
patients received OKT3 for treating episodes of rejection; 
episodes of moderate/severe rejection were treated with 
methylprednisone 1 g IV/day for three days followed by 
prednisone 0.5 – 1 mg/day until the biopsy revealed 
normal results.
Monitoring rejection - Patients were routinely submitted 
to endomyocardial biopsies performed based on the 
following schedule: once a week in the fi rst month; 
once a fortnight in the second month; once a month 
for the next four months, and every two months during 
the fi rst year. Additional biopsies were performed when 
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clinical changes or fi ndings suggested organ rejection 
according to objective procedures (physical examination, 
electrocardiogram and echocardiogram)
RESULTS
Characteristics of the patients - The clinical profi le of 
patients who developed neoplasms is shown in Table 2.
Twenty-three patients out of the 106 (21.6%) studied 
developed neoplasms. Mean follow-up of these 23 patients 
was 73.1 months (ranging from 11 to 192 months).
Mean age of patients at the time of transplantation 
was 52.04 years (ranging from 29 to 62 years). Out 
of the patients who developed cancer, 22 were male 
(95.6%) and only one patient (4.4%) was a female. 
Patients who developed neoplasms had undergone 
transplantation for treating the following heart conditions: 
idiopathic dilated cardiomyopathy – 12 patients (52.1%); 
ischemic cardiomyopathy – 7 patients (30.4%); Chagas’ 
cardiomyopathy – 2 patients (8.6%); post-radiotherapy 
Table 1 – Immunosuppressive Protocol
Drug Initial Dose Maintenance Dose
Cyclosporine A
Dose of 4-6 mg/kg body weight/day from the 4th post-operative day on, 
adjusted based on plasma levels (variation of 200-300 ng/mL in the fi rst 
three months).
Maintenance of plasma levels between 
100-200 ng/mL within the 4th – 8th 
month and between 100-150 ng/mL in 
the following months.
Azathioprine
Dose of 2-2.5 mg/kg body weight/day PO preceded by 4 mg/kg body weight 
in the immediate pre-operative period. Lower dosages in the presence of 
leukopenia, thrombocytopenia or liver dysfunction 
Methylprednisolone
Dose of 500 mg IV followed by 750 mg – 1 g from the intraoperative period 
to the third postoperative day.
Prednisone
Dose of 1-1.5 mg/kg body weight/day PO from the fourth postoperative 
day on.
Minimum dose of 10 mg/day at the six-
month follow-up and minimum daily dose 
or no drug one year following surgery.
Table 2 – Clinical profi le of patients who developed cancer
# of the
patients
Age
(years)
Sex Cardiomyopathy Smoking
Disease 
extension
Time between 
transplantation/
diagnosis (months)
Histological 
type
Treatment
Survival following 
transplantation 
(months)
Outcome
1 47 M Dilated N Localized 116 Skin BCC  Surgical 192 Alive
2 59 M Dilated N Localized 75 Skin SCC Surgical 168 Alive
3 54 M Dilated N Localized 24 Skin BCC Surgical 48 Death 
4 55 M Dilated N Localized 48 Skin SCC Surgical 143 Alive
5 62 M Dilated Y Localized 43 Skin SCC Surgical 93 Death**
6 55 M Ischemic Y Localized 58 Skin BCC Surgical 98 Death**
7 49 M Hypertensive N Localized 23 Skin SCC Surgical 45 Death**
8 56 M Ischemic Y Localized 43 Skin BCC Surgical 83 Alive
9 50 M Chagas N Localized 55 Skin SCC Surgical 72 Alive
10 56 M Dilated N Localized 63 Skin BCC Surgical 72 Alive
11 59 M Dilated N Localized 5 Skin SCC Surgical 57 Alive
12 48 M Dilated  N  Localized 89 Skin SCC Surgical 144 Alive
13 55 M Ischemic Y  Localized 60 Skin SCC Surgical 78 Alive
14 43 M Dilated Y Localized 79 DLPT/CEC CT 84 Death/Ca
15 60 M Dilated Y Advanced 50 Lung RT 70 Death/Ca
16 47 M Ischemic N Advanced 17 Prostate Adenoc Surgical 29 Death/Ca
17 55 M Ischemic Y  Advanced 22 Prostate  Surgical 44 Death/Ca
18 60 M Ischemic Y  Advanced 19 Adenoc * 22 Death/Ca
19 56 M Chagas N  Advanced 36 SCC/esophagus RT 38 Death/Ca
20 58 M Dilated N  Advanced 9 Adenoc Breast CT 11 Death/Ca
21 45 M Dilated N  Advanced 11 Adenoc * 11 Death/Ca
22 29 F Post-partum N  Localized 75 PTLD & 75 Death** 
23 39 M Dilated Y  Localized 39 PTLD & 57 Death/Ca
* support treatment and diagnosis by necropsia, ** Causes of death  other than neoplasms. BCC– basal cell carcinoma; SCC– squamous cell carcinoma; 
Adenoc – adenocarcinoma; RT– radiotherapy; CT– chemotherapy
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cardiomyopathy: 1 patient (4.3%) and hypertrophic 
cardiomyopathy: 1 patient (4.3%). Mean time between 
transplantations and detection of the neoplasm was 44.9 
months (ranging from two to 116 months).
Table 3 shows the distribution of frequencies and types 
of câncer found.
Point and interval estimates of mean survival (in 
months) after heart transplantation applying the Kaplan-
Meier analysis are shown in Table 4. Estimate mean 
survival of subjects with “other types of neoplasms” 
presents an important difference compared to subjects 
with “no neoplasm” and “skin neoplasm”.
Table 3 – Distribution of frequencies according to 
types of cancer
Neoplasm Histological type
# of 
cases
%
Skin
Squamous cell carcinoma 
Basal cell carcinoma
8
5
34.80%
21.70%
So
lid
 Tu
m
or
s
Prostate
Lung
Breast  
Esophagus
Adenocarcinomas *
Adenocarcinoma
Squamous cell carcinoma
Adenocarcinoma
Squamous cell carcinoma
2
1
1
1
2
8.60%
4.30%
4.30%
4.30%
8.60%
PTPD 3 13.40%
Total 23 100%
* The primary sites of metastatic adenocarcinoma of two patients 
remained unknown
Patients’ survival - Survival of heart transplant patients 
is examined based on the survival function provided by 
the Kaplan-Meier analysis. Figure 1 shows survival of 
patients with “no neoplasm”, with “skin neoplasm” and 
with “other types of neoplasms” (solid tumors and PTLD). 
The fi gure also shows that the likelihood of survival is 
higher for those with “skin neoplasm” and “no cancer” 
than for those with “other types of neoplasms”.
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Fig. 1 – Kaplan-Meier Survival Function
Table 4 - Statistics for length of survival following 
heart transplantation
Factors Mean Confi dence Interval (95%)
(months) Lower limit Upper limit
With other types of neoplasm 48.82 31.96 65.67
No neoplasm 107.37 91.84 122.90
With skin neoplasm 146.95 110.57 183.33
DISCUSSION
 According to the literature, the incidence of malignant 
neoplasms is approximately 1-2% a year in patients who 
undergo heart transplantation. Skin tumors are the most 
frequent type observed in organ transplant recipients 
and include squamous cell carcinomas, basal cell 
carcinomas, melanomas and Merkel’s cell carcinoma19-
22. Post-transplant lymphoproliferative diseases (PTLD) 
ranks second. 
Solid tumors ranks third following those two types 
of tumors that make up most of de novo malignant 
tumors observed in organ transplant recipients. Solid 
tumor cancers are classified in two groups: those 
whose incidence is similar to that found in comparable 
groups from the general population – they include lung 
carcinoma, breast carcinoma, prostate cancer and brain 
cancer – and those whose incidence in organ transplant 
recipients is higher – they include renal cancer (in renal 
transplant recipients) and genital cancer in women 
who present uterine cervix carcinomas, perianal/anal 
carcinomas and vulvar carcinomas2.  Recent statistical 
data show that colon carcinoma has a higher incidence 
in transplant recipients than in the general population29 
and that cancer of the ovary is the only neoplasm with 
lower incidence in the population of transplant patients 
compared to the general population 30-33.
The incidence of malignant cancer in this small sample 
of 106 patients submitted to heart transplantation was 
1.35% per year. Nonmelanoma skin carcinoma was the 
most common type. It was observed in 56.5% of the 
subjects with neoplasms, in accordance to rates described 
by the international literature. Excessive sun exposure is a 
risk factor for developing skin cancer as shown by several 
studies that indicate an increased risk of approximately 
21 fold in areas overexposed to sunlight12.16.17.21-23. The 
frequency observed in this sample may be related to 
climate conditions in Brazil, where most of the days are 
sunny. Actually, statistical data from the Ministy of Health 
show that the incidence of skin cancer is the highest 
amongst different types of tumor in this country and the 
estimate risk for developing it in 2005 is 62 cases for each 
100,000 men and 60 for each 100,000 women33.
Post-transplant lymphoproliferative diseases, PTLD, 
represent the second most common type of neoplasm 
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developed by transplant recipients34-36.  Most cases of PTLD 
develop within the fi rst year post-transplant and it seems 
to be related to the Epstein-Barr virus (EBV). A minority 
of patients with EBV-negative PTLD present the same 
distribution over a period of ten years after transplantation37-
40. There may be a predominance of T or B cells with 
monomorphic or polymorphic standard in PTLD 36. The 
most benign form often incidentally found in transplant 
pediatric recipients is hyperplasia of the tonsils. PTLD can 
develop in single or multiple anatomical sites. It may involve 
solid organs or lymphonodes or it may histologically vary 
from hyperplasic lesions to lymphomas36,41-44.
Some factors associated with better prognosis are: 
to be younger at the time that the disease arises; to be 
located in a single anatomical site; involvement limited 
to the graft and to be a patient who may have the doses 
of immunosuppressive agents reduced45. On the other 
hand, involvement of the central nervous system is 
related to a poorer prognosis46,47. Some studies show that 
patients with EBV-negative neoplasm that received OKT3 
as induction immunosuppressive therapy may present a 
higher risk for developing PTPD45,48,49.
In this study, three patients developed PTPD (13.04% 
of all types of neoplasm diagnosed). One of them eventually 
died because of other complications (acute rejection, 
infection by P carinii, and disseminated intravascular 
coagulation). PTLD had affected his mediastin and he 
also presented reactional hyperplasia with expression 
of the Epstein-Barr virus and infiltration of atypical 
lymphomononuclear cells in the splenic parenchyma.
The necropsy of another patient who eventually died 
while studies were being performed to reach a diagnosis 
confi rmed PTPD. It also showed liver involvement and the 
Epstein-Barr virus infection. The biopsy of a third patient 
revealed a comprehensive infi ltration of the anorectal 
mucosa, histopathological and immunohistochemical 
studies resulted in diagnosis of PTLD with pattern of 
polymorphic B-cell lymphoma. The neoplasm was also 
EBV-positive.
Solid tumors were more commonly found than PTLD 
and represented 30.1% of the neoplasms diagnosed. 
The seven types of neoplasm developed by this 
population submitted to cardiac transplantation were: 
prostate adenocarcinoma: 02 patients, lung squamous 
cell carcinoma: 01 patient, breast adenocarcinoma: 
01 patient, esophagus carcinoma: 01 patient and 
disseminated metastatic neoplasm (adenocarcinoma) 
with unknown primary site: 02 patients. Relevant facts 
observed in patients with prostate cancer were the relative 
early development of the disease after the transplantation 
(mean interval of 19.5 months), mean age (52 years) 
below that presented by subjects in the general population 
that develop cancer (72 years) 26 and short survival after 
diagnosis (mean of 36.5 months).
Prostate cancer is the second most common neoplasm 
in men from the general population and the third in the 
population submitted to transplantation. At the time 
of diagnosis, lung and esophagus carcinomas were in 
advanced stage. In transplant patients, lung cancer is 
biologically aggressive – it presents early metastatic 
dissemination and results in advanced stage at the time of 
diagnosis5,9,24. Breast cancer, similarly to what is observed 
regarding neoplasms in transplant recipients, affects these 
patients at age below to that presented by the general 
population for the same disease and is more aggressive. 
Furthermore, a higher percentage of men with breast 
cancer has been identifi ed in the transplant recipients 
compared to its incidence in the general population50,51. 
It is common to have transplant candidates with 
previous history of breast cancer or active breast 
cancer52,53. A recent study examined possible transplant 
recipients who had had breast cancer and that had been 
submitted to appropriate interventions with intention to 
cure based on tumor staging53. All patients had to wait 
fi ve years or more before transplantation. The recurrence 
rate for patients with stage I or II neoplasms ranged from 
5 to 8% but it increased to 64% in patients with stage III 
disease53. Results of that study suggest that in the presence 
of stage III breast cancer or further there is absolute 
contraindication for transplantation whereas patients with 
previous history of stage I or II breast cancer submitted 
to adequate curative treatment and prolonged transplant 
waiting time can be transplant candidates.
In our study there was a male patient with breast 
adenocarcinoma with previous history of breast cancer 
that had been treated with surgery associated with 
radiotherapy. The neoplasm was considered cured and 
the heart transplantation was indicated for treating 
an end-stage post-radiotherapy cardiomyopathy. Nine 
months after the transplant we observed a recurrence of 
the breast tumor. All patients who developed tumors in 
solid organs died because of the neoplasm.  
Worth of mention is a study carried out by Brazilian 
researchers that examined the incidence and the 
characteristics of neoplasms following a heart transplantation 
for treating chronic Chagas’ disease compared to heart 
transplantation for treating other cardiomyopathies54. 
Ninety-one patients were studied and 16 presented 
Chagas’ cardiomyopathy. Six out of the 16 patients 
(37.5%) developed malignant neoplasms (post-transplant 
lymphoproliferative disease: 03 patients, Kaposi’s sarcoma: 
two patients, squamous cell carcinoma: 01 patient) 
detected during post-transplant clinical follow-up that lasted 
25.3 ± 2.1 months compared to two out of the 75 patients 
(2.7%) from the group that presented cardiomyopathy 
non-related to Chagas’ disease. These latter ones presented 
neoplasms (post-transplant lymphoproliferative disease 
and a schwannoma affecting the skin) during a 34.6 ± 
3.6 months of clinical post-transplant follow-up. The study 
concludes that the incidence of malignant neoplasms is 
higher in patients with Chagas’ cardiomyopathy submitted 
to cardiac transplantation. 
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In our study, chronic Chagas’ cardiomyopathy was the 
reason for indication of heart transplant in 31 patients 
(29.2% or 31 out of 106 patients). Only two out of 
the 31 (6.4%) developed a neoplasm (skin cancer and 
esophagus cancer).
A consensus for surveillance of neoplasms in transplant 
recipients was recently published at the American Journal 
of Transplantation54. Recommendations include annual 
chest x-ray, Pap smear for women over the age of eighteen 
years for detecting cervical dysplasia or cancer; biennial 
mammograms beginning at age 40 for high-risk patients 
and at age 50 for those with lower risk for developing 
breast cancer, initial colonoscopic examination at age 
50 and every fi ve years thereafter or in the presence of 
symptoms or guaiac-positive stools. All patients with 
primary sclerosing cholangitis should undergo annual 
colonoscopy in the presence of chronic intestinal disease. 
In the presence of intestinal polyposis, recipients should 
undergo colonoscopy every 6 months until all polyps 
are cleared, at which point the interval follow-up can be 
increased. Annual prostate examinations should include 
digital examination and serum PSA testing. A good 
physical examination of the body surface to detect the 
presence of previous or of newly developed skin lesions. 
Other recommendations can be added such as avoidance 
of excessive exposure to sunlight, use of sun protection 
fi lters and guidelines to perform a self skin examination.
With base on the patients studied, it is concluded 
that:
The incidence of neoplasms in patients who undergo 
heart transplantation is high compared to the general 
population.
Skin neoplasms are the most frequent type found in 
these patients, differently  from what is observed in the 
general population in which the squamous cell carcinoma 
is more common. 
The incidence of lymphoproliferative diseases in the 
group studied was not as predominant as reported in 
the literature.
Differently from skin neoplasms, solid tumors and 
lymphoproliferative diseases in the population that 
underwent transplant may be important causes of death 
in this group of patients.
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